4//SEC Filing
Esposito Pamela 4
Accession 0000950170-25-081201
CIK 0001815442other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 6:30 PM ET
Size
8.7 KB
Accession
0000950170-25-081201
Insider Transaction Report
Form 4
Esposito Pamela
Director
Transactions
- Exercise/Conversion
Common Stock
2025-06-03$29.55/sh+5,000$147,750→ 5,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-03−5,000→ 24,127 totalExercise: $29.55Exp: 2030-09-03→ Common Stock (5,000 underlying) - Sale
Common Stock
2025-06-03$49.04/sh−5,000$245,186→ 0 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001744425
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 6:30 PM ET
- Size
- 8.7 KB